FDA Grants Accelerated Approval To Novartis's Asciminib For Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Clinical Trial Shows 25% Major Molecular Response Rate At 24 Weeks Compared To 13% For Bosutinib
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted accelerated approval to Novartis's drug Asciminib for treating Philadelphia chromosome-positive chronic myeloid leukemia. Clinical trials showed a 25% major molecular response rate at 24 weeks, outperforming Bosutinib's 13%.
October 29, 2024 | 5:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Novartis received FDA accelerated approval for Asciminib, a treatment for Philadelphia chromosome-positive chronic myeloid leukemia, with superior trial results compared to Bosutinib.
The FDA's accelerated approval of Asciminib is a significant regulatory milestone for Novartis, likely boosting investor confidence. The drug's superior performance in clinical trials compared to Bosutinib suggests a competitive advantage in the market.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90